|
Clinical Characteristics of Patient Population (n = 10) |
||||||
| Case No. |
Age |
CV risk |
Radiotherapy |
Baseline LVEF (%) |
Post Chemothx LVEF (%) |
Trastuzumab Duration |
|
|
||||||
| 1 |
33 |
None |
Yes |
55 |
52 |
4 months |
| 2 |
41 |
HTN |
Yes |
60 |
58 |
5 months |
| 3 |
27 |
None |
Yes |
54 |
56 |
4 months |
| 4 |
39 |
None |
Yes |
65 |
62 |
3 months |
| 5 |
44 |
Lipids |
Yes |
58 |
55 |
4 months |
| 6 |
38 |
None |
Yes |
56 |
52 |
5 months |
| 7 |
56 |
HTN |
Yes |
60 |
62 |
3 months |
| 8 |
45 |
HTN |
Yes |
54 |
55 |
4 months |
| 9 |
32 |
None |
Yes |
55 |
52 |
5 months |
| 10 |
40 |
HTN |
Yes |
60 |
58 |
4 months |
|
CV, cardiovascular; LVEF, left ventricular ejection fraction; chemothx, chemotherapy; HTN, hypertension. | ||||||
Fallah-Rad et al. Journal of Cardiovascular Magnetic Resonance 2008 10:5 doi:10.1186/1532-429X-10-5 |
||||||